Literature DB >> 18422943

Increased levels of gamma-glutamylamines in Huntington disease CSF.

Thomas M Jeitner1, Wayne R Matson, John E Folk, John P Blass, Arthur J L Cooper.   

Abstract

Transglutaminases (TGases) catalyze several reactions with protein substrates, including formation of gamma-glutamyl-epsilon-lysine cross-links and gamma-glutamylpolyamine residues. The resulting gamma-glutamylamines are excised intact during proteolysis. TGase activity is altered in several diseases, highlighting the importance of in situ enzymatic determinations. Previous work showed that TGase activity (as measured by an in vitro assay) and free gamma-glutamyl-epsilon-lysine levels are elevated in Huntington disease (HD) and that gamma-glutamyl-epsilon-lysine is increased in HD CSF. Although free gamma-glutamyl-epsilon-lysine was used in these studies as an index of in situ TGase activity, gamma-glutamylpolyamines may also be diagnostic. We have devised methods for the simultaneous determination of four gamma-glutamylamines in CSF: gamma-glutamyl-epsilon-lysine, gamma-glutamylspermidine, gamma-glutamylputrescine, and bis-gamma-glutamylputrescine and showed that all are present in normal human CSF at concentrations of approximately 150, 670, 40, and 240 nM, respectively. The high gamma-glutamylspermidine/gamma-glutamylputrescine and gamma-glutamylspermidine/bis-gamma-glutamylputrescine ratios presumably reflect in part the large spermidine to putrescine mole ratio in human brain. We also showed that all four gamma-glutamylamines are elevated in HD CSF. Our findings support the hypotheses that (i) gamma-glutamylpolyamines are reflective of TGase activity in human brain, (ii) polyamination is an important post-translational modification of brain proteins, and (iii) TGase-catalyzed modification of proteins is increased in HD brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422943      PMCID: PMC2574808          DOI: 10.1111/j.1471-4159.2008.05350.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

Review 1.  The role of transglutaminases in neurodegenerative diseases: overview.

Authors:  Arthur J L Cooper; Thomas M Jeitner; John P Blass
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

Review 2.  Transglutaminases in disease.

Authors:  Soo Youl Kim; Thomas M Jeitner; Peter M Steinert
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

3.  N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

Authors:  T M Jeitner; M B Bogdanov; W R Matson; Y Daikhin; M Yudkoff; J E Folk; L Steinman; S E Browne; M F Beal; J P Blass; A J Cooper
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

4.  A sensitive fluorometric assay for tissue transglutaminase.

Authors:  T M Jeitner; H L Fuchsbauer; J P Blass; A J Cooper
Journal:  Anal Biochem       Date:  2001-05-15       Impact factor: 3.365

5.  N(epsilon)(gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia.

Authors:  Z Nemes; L Fésüs; A Egerházi; A Keszthelyi; I M Degrell
Journal:  Neurobiol Aging       Date:  2001 May-Jun       Impact factor: 4.673

6.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Authors:  Marcela V Karpuj; Mark W Becher; Joe E Springer; Dorothee Chabas; Sawsan Youssef; Rosetta Pedotti; Dennis Mitchell; Lawrence Steinman
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

7.  Tissue transglutaminase is increased in Huntington's disease brain.

Authors:  M Lesort; W Chun; G V Johnson; R J Ferrante
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

8.  Activation of rho through a cross-link with polyamines catalyzed by Bordetella dermonecrotizing toxin.

Authors:  M Masuda; L Betancourt; T Matsuzawa; T Kashimoto; T Takao; Y Shimonishi; Y Horiguchi
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

9.  Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase.

Authors:  Jedidah W Danson; Mary Lynn Trawick; Arthur J L Cooper
Journal:  Anal Biochem       Date:  2002-04-15       Impact factor: 3.365

10.  'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.

Authors:  P G Mastroberardino; C Iannicola; R Nardacci; F Bernassola; V De Laurenzi; G Melino; S Moreno; F Pavone; S Oliverio; L Fesus; M Piacentini
Journal:  Cell Death Differ       Date:  2002-09       Impact factor: 15.828

View more
  19 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

2.  Physio-pathological roles of transglutaminase-catalyzed reactions.

Authors:  Mariangela Ricotta; Maura Iannuzzi; Giulia De Vivo; Vittorio Gentile
Journal:  World J Biol Chem       Date:  2010-05-26

3.  Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Authors:  Ashish Kumar; Andrew Kneynsberg; Janusz Tucholski; Giselle Perry; Thomas van Groen; Peter J Detloff; Mathieu Lesort
Journal:  Exp Neurol       Date:  2012-06-12       Impact factor: 5.330

4.  Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.

Authors:  Antonio Martin; Giulia De Vivo; Vittorio Gentile
Journal:  Int J Alzheimers Dis       Date:  2011-02-16

Review 5.  Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.

Authors:  Gary E Gibson; Anatoly Starkov; John P Blass; Rajiv R Ratan; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2009-08-26

Review 6.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

7.  Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.

Authors:  Erika N Ebbel; Nancy Leymarie; Susan Schiavo; Swati Sharma; Sona Gevorkian; Steven Hersch; Wayne R Matson; Catherine E Costello
Journal:  Anal Biochem       Date:  2010-01-13       Impact factor: 3.365

Review 8.  Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

Authors:  Amit Kumar; Manisha Vaish; Rajiv R Ratan
Journal:  Drug Discov Today       Date:  2014-03-21       Impact factor: 7.851

9.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

10.  Transglutaminase 6: a protein associated with central nervous system development and motor function.

Authors:  Helen Thomas; Konrad Beck; Magdalena Adamczyk; Pascale Aeschlimann; Martin Langley; Radu C Oita; Lars Thiebach; Martin Hils; Daniel Aeschlimann
Journal:  Amino Acids       Date:  2011-10-08       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.